Androgen Ablation Combined With CTLA-4 Blockade-Based Immunotherapy as a Treatment for Prostate Cancer
Abstract
Manipulations capable of repealing host tolerance to induce T cell-mediated prostate tissue-specific responses are of central importance to immunotherapeutic approaches to prostate cancer treatment. Hence in the current proposal, we test whether androgen ablation (by castration) can induce T cell responses targeting murine prostate epithelial and tumor cells. To date, we have found that castration of TRAMP mice results in prostate and tumor infiltration by antigen presenting cells (APC's) as well as CD4+ and CD8+ T cells. These studies complete our original Specific Aim 1 and suggest that castration can prime host responses amenable to immunotherapeutic potentiation. Further studies proposed in our original Specific Aims 2 and 3 will address the potential of androgen ablation to facilitate/potentiate novel immunotherapies, including manipulations that license APC's or prevent T cell downregulation, for prostate cancer treatment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2001
- Accession Number
- ADA391127
Entities
People
- Eugene D. Kwon
Organizations
- Loyola University Chicago